AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 22 min read$JNJ

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in d

Johnson & Johnson (JNJ) presented two-year data from the Phase 3 ICONIC-TOTAL study, showing ICOTYDE® (icotrokinra) sustained skin clearance in high-impact plaque psoriasis. Key results: 60% scalp, 89% genital, and 63% hand/foot clearance at Week 112. Safety profile remained consistent. Data was shared at the EADV Congress 2026.

Original reporting
gurufocus.com
Published Oct 2, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The data could expand JNJ's dermatology portfolio and provide a differentiated oral therapy, influencing analyst expectations.

02

Market read

Positive trial results may lift JNJ's stock and benefit peers in dermatology and biotech.

03

What to watch

Potential competition from existing biologics and the need for regulatory approval could temper upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Johnson & Johnson announced the data at the EADV Congress, highlighting ICOTYDE as the first oral peptide targeting IL‑23R for plaque psoriasis.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson released new two-year Phase 3 data for its oral peptide ICOTYDE showing high skin clearance rates in hard‑to‑treat psoriasis sites.

Expected impact

likely upward pressure as investors price in expanded product potential

Evidence & confidence

Robust efficacy and safety data for a first‑in‑class oral peptide address a large unmet need, which could boost JNJ's dermatology franchise.

Market effects

Sector

Dermatology and broader biotech sectors may see heightened interest in oral peptide platforms.

Regional

U.S. and European markets could see modest gains in healthcare stocks.

Global

Limited to companies with similar pipeline strategies; no broad macro effect.

Counterpoint

What could challenge this read

If pricing or reimbursement challenges arise, the data may not translate into meaningful revenue.

Key entities

  • Company
    Johnson & Johnson

    US‑listed healthcare conglomerate releasing trial data.

  • Product
    ICOTYDE (icotrokinra)

    Oral peptide targeting IL‑23 receptor for plaque psoriasis.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 2
$JNJMed

J&J reports two-year psoriasis drug data for high-impact sites

Johnson & Johnson (JNJ) reported two-year Phase 3 study results for ICOTYDE, showing significant skin clearance in patients with psoriasis in high-impact areas. The drug achieved 60% complete scalp clearance, 89% genital clearance, and 63% hand/foot clearance at Week 112. Overall clearance rates improved from 57% to 70% over the study period. The company noted consistent safety findings with no new signals.

investing.com2 min
OCT 2
$JNJMed

Johnson & Johnson Reports Sustained Psoriasis Clearance

Johnson & Johnson (JNJ) reported Phase 3 trial results for ICOTYDE, showing 70% of patients achieved clear or almost clear skin after 112 weeks. The treatment demonstrated effectiveness in difficult-to-treat areas and maintained its safety profile. The ICONIC-TOTAL study included adults and adolescents with moderate to severe plaque psoriasis.

grafa.com1 min
OCT 2
$JNJMed

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Johnson & Johnson (JNJ) reported two-year data from the Phase 3 ICONIC-TOTALa study, showing ICOTYDE® (icotrokinra) sustained skin clearance in plaque psoriasis. 60% of scalp psoriasis and 89% of genital psoriasis patients achieved complete clearance at Week 112. The drug showed a favorable safety profile, according to the company.

prnewswire.com2 min
SEP 30
$JNJMedAI 8/10

What Does Johnson & Johnson (JNJ) Long Term IMAAVY Data Mean For gMG?

Johnson & Johnson (JNJ) presented two-year data on IMAAVY for generalized myasthenia gravis, showing sustained disease control and safety in adolescents. The company also shared insights on adult treatment patterns. JNJ aims to address unmet needs in immune and neuromuscular disorders, with the data supporting its immunology strategy.

simplywall.st2 min
SEP 29
$JNJMedAI 8/10

Johnson & Johnson Presents New Data Reinforcing Sustained Disease Control and Improved Daily Function Achieved with IMAAVY in Generalized Myasthenia Gravis

Johnson & Johnson (JNJ) presented new data on IMAAVY® for generalized myasthenia gravis (gMG) at the 2026 MGFA and AANEM meetings. Two-year results from a Phase 2/3 study showed sustained disease control in adolescents, with improvements in daily function and muscle strength, and reduced corticosteroid use. No new safety signals were identified. HCPs cited fluctuating symptom control as a key reason for transitioning to IMAAVY, with 73.2% of patients reporting significant improvement.

marketscreener.com2 min